RxDoctor Payments Data

Eva Tsalikian

Pediatric Endocrinology · Iowa City, IANPI 1619963949

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (43.5%), education and food and beverage — rather than concentrated in one kind of arrangement. 3 manufacturers reported payments, led by Pfizer at 43.5% of the total.

$230in general payments, 2019–2025

Across 5 payments — averaging $46.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$100
  • Novo Nordisk$97
  • Biomarin Pharmaceutical Inc.$33
$956,929in research payments, 2019–2025

Across 598 payments — averaging $1600.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim$304K
  • Takeda Pharmaceuticals U.S.A., Inc.$170K
  • Novo Nordisk AS$130K
  • OPKO Pharmaceuticals, LLC$93K
  • Abbott$64K
  • Astrazeneca UK Limited$58K
  • plus $138K from 6 others

What the payments were for

  • Consulting fees$10043%
  • Food & beverage$3314%
  • Education$9742%

General payments by program year

20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer1$100
Novo Nordisk3$97
Biomarin Pharmaceutical Inc.1$33

How this compares

Too few pediatric endocrinology providers in Iowato place this figure against a meaningful peer group, so we don't.

Other pediatric endocrinology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →